Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.

Date publication

juillet 2024

Journal

Journal of geriatric oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier , Dr SCHOTT Roland

Tous les auteurs :
Cabart M, Mourey L, Pasquier D, Schneider S, Léna H, Girard N, Chouaid C, Schott R, Hiret S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Pérol M, Bosquet L, Cabarrou B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39068144

Résumé

In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical Economics (ESME) platform on Lung Cancer (LC), the objective is to provide an overview of the management and the prognosis of older patients with advanced or metastatic non-small cell lung cancer (AM-NSCLC) in a real-world context.

Mots clés

Chemotherapy, EGFR mutation, Immunotherapy, Non-small cell lung cancer, Older patients, Pattern of care, Prognosis, Targeted therapy

Référence

J Geriatr Oncol. 2024 07 26;:101819